Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Baudax Bio, Inc.BXRX · Entity 109081 | Director | June 15, 2022 | June 17, 2022 |
| Medicus Pharma Ltd.MDCX · Entity 7770 | Director | June 03, 2026 | June 04, 2026 |
| SELLAS Life Sciences Group, Inc.GALE · Entity 4313 | Director | October 10, 2017 | October 10, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Baudax Bio, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,534 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 39,473 · Balance 42,534 F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.
Medicus Pharma Ltd.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2031-06-03 | Direct | 50,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 50,000 · Balance 50,000 F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
SELLAS Life Sciences Group, Inc.
Report date October 10, 2017 · Filed October 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,154 |
Reported balance
After 2017-10-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-10-10 · Grant · Acquired 15,472 · Balance 38,154 F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPECTRUM PHARMACEUTICALS INC
Report date July 31, 2023 · Filed August 01, 2023
Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 1
1 source rowRow 1 · 2023-07-31 · Disposition to issuer · Disposed 67,660 · Balance 0 F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,
F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.
Societal CDMO, Inc.
Report date April 08, 2024 · Filed April 09, 2024
Section 16 reporting ended · disclosed 2024-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-04-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-08 · Other · Disposed 190,002 · Balance 73,620 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest. Row 2 · 2024-04-08 · Disposition to issuer · Disposed 73,620 · Balance 0 F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-08 · Disposition to issuer · Disposed 118,182 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-08 · Disposition to issuer · Disposed 27,229 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest.
F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2018 Filed May 8, 2018 21:29 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantCommon Stock | 6,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000186 · edgar.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,183 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on May 4, 2019. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| May 04, 2018 Filed May 10, 2018 23:00 UTC Amendment | Societal CDMO, Inc. REPH · Entity 92137 | GrantStock Option (right to buy) · Derivative | 8,965 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000198 · edgar.xml · derivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,965 Underlying: Common Stock · 8,965 shares Expires 2028-05-04 F1 · shares: This amended Form 4 is being filed to correct a typographical error in the number of stock options acquired on May 4, 2018 as reported on the Form 4 filed on May 8, 2018. F2 · derivative.exercise_date: The stock option will vest on May 4, 2019. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:48 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 15,472 | $0.38 | $5,879.36 |
DisclosureSEC source: 0001394548-17-000028 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,154 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:44 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 9,866 | $0.59 | $5,820.94 |
DisclosureSEC source: 0001394548-17-000025 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,682 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:44 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000025 · primary_doc.xml · derivative · entry 2 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:27 UTC | Societal CDMO, Inc. REPH · Entity 92137 | GrantRestricted Stock Units · Derivative | 13,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-17-000939 · edgar.xml · derivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,274 Underlying: Common Stock · 13,274 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. F2 · derivative.expiration_date: The restricted stock units vest on May 12, 2018. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:53 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 9,870 | $0.59 | $5,823.30 |
DisclosureSEC source: 0001394548-17-000012 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,816 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan, priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 23:07 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 2,946 | $1.98 | $5,833.08 |
DisclosureSEC source: 0001394548-17-000008 · primary_doc.xml · nonDerivative · entry 1 Ashton William · CIK 0001474553 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.